Novo Nordisk (CPSE:NOVO B) Set To Unveil New Obesity Data At ObesityWeek 2026
Yahoo Finance · Nov 3, 2026 · Novo Nordisk A S (NVO)
Novo Nordisk (CPSE:NOVO B) plans to unveil new obesity portfolio data at ObesityWeek 2026 in early November. The firm is set to share real-world Wegovy findings that cover treatment experiences from pediatric patients through to elderly adults. Investigational CagriSema results are expected to feature new weight-loss endpoints and outcomes in telehealth treatment settings. Fresh Wegovy and CagriSema data at ObesityWeek 2026 represents only one part of Novo Nordisk's wider obesity story. Our...
Not investment advice. Headline and summary only, not a full reprint.